NY-AQARA
19.10.2021 15:02:06 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the launch of its Professional Partners Program for smart home installers and integrators. Utilizing Aqara’s decade-long experience in the smart home industry and its comprehensive suite of smart home products, advanced technologies, solutions, and tools, the Professional Partners Program aims to support professional installers in enhancing their service offerings and growing their businesses. The Program also welcomes the broader professional community, such as shading control installers, smart lock locksmiths, home theater installers, interior designers and electricians, to join the Aqara partner network.
With years of experience in offering high-quality products to global consumers, Aqara now seeks to join forces with the professional community to boost adoption of the smart home technology worldwide. As part of Aqara Partners Program, participants will enjoy:
- Priority access to new Aqara products
- Special promotional pricing on certain products
- Comprehensive product training support and resources
- Opportunity to connect with interested Aqara users in local areas
- Marketing support
Starting in October 2021, Aqara has launched an exclusive Smart Roller Shade Controller Package as the first promotional event within the Professional Partners Program for a limited time. The Smart Roller Shade Controller is the global version of Aqara’s most popular roller shade motor, which is designed to automate a variety of roller blinds and even projector screens. Bound with an Aqara hub, the controller allows roller shades to be controlled by mobiles, voice commands (Apple Siri, Google Assistant, Yandex Alice, Naver Clova, etc.), pre-set schedules, and via home automations in which roller shades could be triggered by illumination condition, human motion, room temperature, etc.
To learn more about the Professional Partners Program or register for the Smart Roller Shade Controller Package, please visit our website .
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. The Company provides comprehensive smart home products and solutions that are beautifully designed, long-lasting, and easy to use. Products range from a variety of smart sensors to switches, curtain controllers, and smart door locks. Over the last few years, Aqara has opened more than 600 Aqara stores to provide more personalized smart home solutions for individual households and businesses.
Aqara currently serves more than 2 million customers worldwide, with distribution partners in the United States, EU, Russia, Southeast Asia, Korea, and China. The Company also offers one of the most comprehensive suite of HomeKit compatible smart home solutions in the market, and its products can also be found in Apple Stores across Europe and Asia. As the Company continues to expand its global footprint, Aqara hopes to bring more accessible, smart home technology to households around the world.
For more information, please visit our website and follow our social platforms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom